Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 6:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Healthy
Interventions: Dichloroacetate, Genotyping, Leucine, tyrosine; Drug · Genetic · Other
Lead sponsor: University of Florida; Other
Eligibility: 22 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Sepsis, Trauma, Infection
Interventions: 11-gene set; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lynch Syndrome, Lynch Syndrome I, Lynch Syndrome II, Lynch Syndrome I (Site-specific Colonic Cancer), HNPCC, HNPCC Gene Mutation, Hereditary Cancer Syndrome, Hereditary Cancer, MLH1 Gene Mutation, MLH1 Gene Deletion+Duplication, MLH1 Loss of Expression, MLH1 Gene Inactivation, MSH2 Gene Mutation, MSH2 Gene Deletion+Duplication, MSH2 Loss of Expression, MSH2 Gene Inactivation, MSH6 Gene Mutation, MSH6 Loss of Expression, MSH6 Gene Inactivation, PMS2 Gene Mutation, PMS2 Gene Inactivation, PMS2 Loss of Expression
Interventions: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System); Diagnostic Test
Lead sponsor: San Raffaele University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Timeline: 2023 – 2034
U.S. locations: 1
States / cities: Monrovia, California

Conditions: Hiv, Kidney Transplant, HIV Reservoir, CCR5
Interventions: Sirolimus + Maraviroc; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: UVB Phototherapy Burn, Insulin-like Growth Factor 1, Aging
Interventions: Insulin-Like Growth Factor 1, No Insulin-Lie Growth Factor 1; Drug · Other
Lead sponsor: Wright State University; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Interventions: 225Ac-PSMA-Trillium (BAY3563254); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 1 more

Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Interventions: Tumor and HLA Profiling; Diagnostic Test
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 21
States / cities: Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more

Conditions: Rheumatoid Arthritis
Interventions: Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira; Other · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pancreatic Ductal Adenocarcinoma
Interventions: ASP2138, Oxaliplatin, Leucovorin, 5-FU, Irinotecan, Gemcitabine, Nab-paclitaxel, Capecitabine; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Durham, North Carolina

Conditions: Hypoxia, Lactic Acidosis
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Precancerous Condition, Stage 0 Cervical Cancer
Interventions: Cervical Papanicolaou Test, Conization, Laboratory Biomarker Analysis; Other · Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Age-Related Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 62
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 53 more

Conditions: Head and Neck Cancer
Interventions: gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, needle biopsy; Genetic · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Insulin Resistance, Obesity
Interventions: Not listed
Lead sponsor: Rockefeller University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia
Interventions: Not listed
Lead sponsor: University of Tennessee, Chattanooga; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Healthy
Interventions: Fish oil + wild orange essential oil supplement, Fish oil supplement; Dietary Supplement
Lead sponsor: dōTERRA International; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Aortic Valve Disease
Interventions: Not listed
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Plano, Texas

Conditions: Rectal Adenocarcinoma, Anal Adenocarcinoma, Anal Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: Castle Biosciences Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-small Cell Lung Cancer
Interventions: fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 29
States / cities: Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more

Conditions: Kidney Transplant Immunosuppression
Interventions: Allosure and TruGraf, Immunosuppression Taper; Diagnostic Test · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Endometrial Cancer
Interventions: BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more

Conditions: Follicular Lymphoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COPD
Interventions: Roflumilast Placebo, Roflumilast; Drug
Lead sponsor: University of Miami; Other
Eligibility: 45 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Pharmacotoxicology of Trichloroethylene Metabolites

Longitudinal Gene Expression Profiling in Adults After Traumatic Injury

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients

Gene Expression Changes In Young and Geriatric Skin

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression

Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer

Genetic Study of Age-Related Macular Degeneration

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules

Research on the Nature, Diagnosis, and Treatment of Obesity and Diabetes

Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions

Omega-3 Supplement and Health Markers

A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease

Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Clonal Evolution in Follicular Lymphoma

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD